Tanvex BioPharma

Trial and FDA signals

• FDA complete response letter Received an FDA complete response letter (BLA 761266, letter dated Jun 23, 2026). FDA BLA 761266 (Jun 23, 2026)
  Evidence (1 event)

  • Jun 23, 2026 · FDA BLA 761266
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Tanvex BioPharma USA, Inc. Attention: Bonnie J. Mills, PhD San Diego, CA (street omitted) Dear Dr. Mills: Please refer to your biologics license application (BLA) dat

Job counts as of Oct 18, 2026. All trial and FDA signals